Reset after RESET: insights from a negative trial in coeliac disease
- PMID: 36898392
- DOI: 10.1016/S2468-1253(23)00007-9
Reset after RESET: insights from a negative trial in coeliac disease
Conflict of interest statement
EFV is secretary of the International Society for the Study of Celiac Disease, is a member of the Advisory Board of the Biocodex Foundation, and is funded by a Kallyope grant unrelated to this study. HJG declares no competing interests.
Comment on
-
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.Lancet Gastroenterol Hepatol. 2023 May;8(5):446-457. doi: 10.1016/S2468-1253(22)00428-9. Epub 2023 Mar 7. Lancet Gastroenterol Hepatol. 2023. PMID: 36898393 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
